Welcome to our dedicated page for Agios Pharmaceuticals SEC filings (Ticker: AGIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Agios Pharmaceuticals, Inc. filings document the regulatory record of a Delaware, Nasdaq-listed commercial-stage biopharmaceutical company focused on rare diseases and hematology. Its 8-K reports furnish operating results, product revenue updates for PYRUKYND® and AQVESME™, business highlights, investor presentations, and Regulation FD disclosures tied to mitapivat commercialization, clinical programs, and regulatory interactions.
Proxy and current-report filings cover annual-meeting proposals, director elections, board-class structure, committee assignments, stockholder voting matters, and compensatory arrangements for directors. Other disclosures address board appointments, pharmacovigilance communications involving PYRUKYND, exhibit filings, and Inline XBRL cover-page data.
Agios Pharmaceuticals, Inc. – Form 144 filing
An unnamed insider intends to sell 1,761 common shares of Agios Pharmaceuticals, Inc. (AGIO) through Morgan Stanley Smith Barney on 24 June 2025. The shares, worth about $60,596, were obtained the same day via the vesting of restricted stock units. With 57.9 million shares outstanding, the proposed sale equates to roughly 0.003 % of total shares, indicating an immaterial ownership change. No other insider sales were reported in the past three months, and the filer certified that no undisclosed adverse information is known.
Agios Pharmaceuticals, Inc. (AGIO) has filed a Form 144 with the U.S. Securities and Exchange Commission disclosing a proposed insider sale under Rule 144.
- Shares to be sold: 1,761 shares of common stock
- Aggregate market value: $60,596
- Approximate sale date: 06/24/2025
- Broker: Morgan Stanley Smith Barney LLC, New York, NY
- Shares outstanding: 57,915,199
- Source of shares: Vesting of restricted stock on 06/24/2025
- Exchange: Nasdaq
The proposed sale represents roughly 0.003% of the company’s outstanding shares, indicating a de-minimis transaction that is unlikely to have a material effect on the company’s capital structure or market liquidity. No prior sales were reported in the past three months, and the filer attests to possessing no undisclosed material adverse information.
Agios Pharmaceuticals, Inc. (AGIO) has filed a Form 144 indicating the intended sale of 1,761 common shares through Morgan Stanley Smith Barney LLC. The shares were acquired via the vesting of restricted stock units on 24 June 2025 and are targeted for sale on the same date. At an aggregate market value of $60,596, the proposed disposition represents roughly 0.003 % of the company’s 57.9 million shares outstanding. No other sales have been reported by the filer during the past three months.
The notice affirms that the seller possesses no undisclosed material adverse information about AGIO at the time of filing, as required under Rule 144. Because the volume and value are immaterial relative to the company’s market capitalization and daily trading volume, the filing is largely routine and unlikely to affect the share price.
Form 4 Filing Overview – Agios Pharmaceuticals (AGIO), 23 Jun 2025
Director Rahul D. Ballal reported several equity-based transactions executed on 18 and 20 June 2025. The filing shows no open-market sales; all movements relate to equity awards and the conversion of previously granted restricted stock units (RSUs).
- Equity Award Grants (18 Jun 2025)
- 2,816 RSUs – vest 100% on 18 Jun 2026.
- 15,768 stock options – exercise price $35.50, vest 100% on 18 Jun 2026, expire 18 Jun 2035.
- RSU Conversion (20 Jun 2025)
- 2,120 shares of common stock acquired at $0 cost via automatic conversion of RSUs granted 20 Jun 2024.
- Post-transaction holdings: 10,112 common shares held directly; zero derivative RSUs remain from the 2024 grant; 15,768 unexercised options and 2,816 unvested RSUs newly awarded.
The transactions increase Ballal’s direct ownership by 2,120 shares and reinforce his long-term incentive alignment through a fresh option package. Because the activity consists solely of routine compensation grants and vesting with no disposals, the immediate market impact is normally limited; however, the additional share ownership may be viewed positively by investors monitoring insider sentiment.
Agios Pharmaceuticals, Inc. (AGIO) – Form 4 filing reports routine equity transactions by director Jeffrey D. Capello.
New equity awards (granted 18-Jun-2025):
- 2,861 Restricted Stock Units (RSUs); vest 100% on 18-Jun-2026.
- 15,768 Non-qualified Stock Options with a $35.50 exercise price; options vest 100% on 18-Jun-2026 and expire 18-Jun-2035.
RSU conversion (20-Jun-2025):
- Capello received 2,120 common shares (Transaction Code “M”) at $0 cost upon full vesting of a June 2024 RSU grant.
Post-transaction ownership (direct):
- 6,073 common shares (includes newly delivered 2,120 shares).
- 2,861 unvested RSUs.
- 15,768 options at $35.50.
The filing reflects standard director compensation and scheduled vesting; no open-market purchases or sales occurred. No change to board composition or strategy was disclosed.
Form 4 filing overview: On 06/23/2025, Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) reported changes in the beneficial ownership of director Kaye I. Foster-Cheek.
- New equity grants (06/18/2025): • 2,816 restricted stock units (RSUs) that vest in full on 06/18/2026. • 15,768 stock options with a $35.50 exercise price, also vesting 100% on 06/18/2026 and expiring 06/18/2035.
- RSU conversion (06/20/2025): 2,120 previously granted RSUs vested and were converted into an equal number of common shares at $0 cost (code M). These shares were added to her direct holdings.
- Post-transaction ownership: • Direct: 7,468 common shares. • Indirect: 2,200 shares held by the Foster Family Revocable Trust.
No shares were sold and no cash purchases were reported. All transactions were equity-based awards or conversions, indicating routine director compensation and continued share ownership.
Agios Pharmaceuticals, Inc. (AGIO) – Form 4 Insider Filing (23 Jun 2025)
Director Jacqualyn A. Fouse reported several equity transactions occurring on 18 Jun 2025 and 20 Jun 2025:
- New awards: 2,816 restricted stock units (RSUs) and 15,768 stock options with a $35.50 exercise price, both vesting 100% on 18 Jun 2026. The options expire on 18 Jun 2035.
- Vested conversion: 2,120 previously granted RSUs (dated 20 Jun 2024) were converted into an equal number of common shares (code “M”), at no cash cost.
- Following these transactions, Fouse now holds 151,340 AGIO common shares directly and continues to hold 2,816 un-vested RSUs and 15,768 un-exercised options.
No sales of common stock occurred; all activity reflects grants or conversions, indicating continued alignment of the director’s incentives with shareholder interests. The size of the awards is typical for a board-level compensation package and is unlikely to materially affect AGIO’s share count or insider-ownership structure.
Agios Pharmaceuticals, Inc. (AGIO) – Form 4 insider filing
Director Maykin Ho reported two equity-compensation events and one share delivery:
- June 18, 2025 – New awards: granted 2,816 restricted stock units (RSUs) that vest 100% on 6/18/2026, and 15,768 stock options with a $35.50 strike, also vesting 100% on 6/18/2026 and expiring 6/18/2035.
- June 20, 2025 – RSU vesting: 2,120 previously granted RSUs (dated 6/20/2024) vested and converted to common shares at no cash cost (reported under code “M”).
Following these transactions Ms. Ho now directly owns 17,032 AGIO common shares and holds the newly granted options and RSUs in addition to the delivered stock. The filing reflects routine director compensation rather than open-market buying or selling; no shares were sold and no cash proceeds were reported.